secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001356576-24-000041
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus resubmits NDA for SPN-830 apomorphine infusion for Parkinson's OFF episodes
--------------------------------------------------------------------------------

- Resubmitted NDA for SPN-830 (apomorphine infusion device) to FDA for continuous treatment of OFF episodes in Parkinson's disease.
- CRL in April 2024 identified two areas needing additional info; no clinical safety or efficacy issues were raised.
- Company believes it has fully addressed the FDA's questions from the CRL.
- If approved, SPN-830 could be an important novel therapy for Parkinson's patients.
- Supernus will continue to work closely with the FDA during the NDA review process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000041/0001356576-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000041/supn-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer